CN104906088B - Application of the berberine in the medicine for preparing treatment t cell lymphoma - Google Patents
Application of the berberine in the medicine for preparing treatment t cell lymphoma Download PDFInfo
- Publication number
- CN104906088B CN104906088B CN201510083058.1A CN201510083058A CN104906088B CN 104906088 B CN104906088 B CN 104906088B CN 201510083058 A CN201510083058 A CN 201510083058A CN 104906088 B CN104906088 B CN 104906088B
- Authority
- CN
- China
- Prior art keywords
- berberine
- cell
- cell lymphoma
- medicine
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to application of the berberine in the medicine for preparing treatment t cell lymphoma.The present invention carries out experiment in vitro using two kinds of t cell lymphoma cell lines, additionally set up t cell lymphoma mouse model and carry out experiment in vivo, confirm that the coptis is known as the effect for suppressing T lymphoma cell strains propagation and tumor-bearing mice lymphoma growth, and inhibitory action is very notable, prompt berberine can be as the active drug for the treatment of t cell lymphoma, and its drug safety has received long-term checking, therefore the present invention provides a kind of new scheme for the treatment of clinical t cell lymphoma.
Description
Technical field
The present invention relates to a kind of new application of berberine, specifically, is related to berberine and is preparing treatment t cell lymphoma
Medicine in application.
Background technology
Berberine (berberine, C20H18ClNO4) it is a kind of ancient Chinese medicine, multiple pathogenic microorganisms can be resisted, it is clinical
On be mainly used in treating bacillary dysentery and enterogastritis.Increasing research shows that berberine is to immune system, painstaking effort now
The disease of guard system, nervous system etc. can play different degrees of improvement result, for example, berberine is reported in correlative study
With anti-arrhythmia, reduce blood pressure, positive inotropic, protection ischemic brain damage, hypoglycemic, anti-inflammatory, suppress platelet aggregation,
Antiulcer, antipyretic etc. act on.Because berberine is also equipped with that toxic side effect is light, advantage that can be long-term use of, it is prompted to have wide
Potential applicability in clinical practice.
T cell lymphoma is that a kind of rare non-Hodgkin lymphoma, pathogenic factor such as HTLV- and Epstein-Barr virus are more in Asian countries
See, showing as T cell with immune method measure cell phenotype is immunized surface markers.
The effect on berberine in terms of t cell lymphoma is treated has not been reported at present.
The content of the invention
It is an object of the invention to provide the new application of berberine, to expand the application of berberine.
To achieve the above object：
The invention provides application of the berberine in the medicine for preparing treatment t cell lymphoma.
As the preference of the present invention, described t cell lymphoma is that T lymphoblastic lymphomas or skin T are thin
Born of the same parents' lymthoma.
The invention provides application of the berberine in medicine is prepared, described medicine is used to suppress T cell in animal body
The growth of lymthoma.
The invention provides application of the berberine in medicine is prepared, described medicine is used to suppress T cell in animal body
The increase of lymphoma mass.
Present invention also offers application of the berberine in medicine is prepared, described medicine is used to suppress t cell lymphoma
The propagation of cell line.
As the present invention a preference, described t cell lymphoma cell line be people T-LBL cell lines Jurkat or
CTCL cell lines H9.
The invention has the advantages that：
1st, application of the berberine in the medicine for preparing treatment t cell lymphoma is provided.The present invention passes through cell in vitro
Experiment and animal experiment in vivo confirm that the coptis is known as and suppress T lymphoma cell strains propagation and tumor-bearing mice lymphoma growth
Effect, and inhibitory action is very notable, prompts berberine can be as the active drug for the treatment of t cell lymphoma, and its medicine is pacified
Full property has received long-term checking, therefore the present invention provides a kind of new scheme for the treatment of clinical t cell lymphoma.
2nd, provide berberine be used for prepare suppress animal body in t cell lymphoma grow medicine in application, especially
It is the increase for suppressing t cell lymphoma volume in animal body.
3rd, application of the berberine in the medicine for suppressing t cell lymphoma cell line propagation is prepared is provided, available for grinding
Study carefully the research such as screening and drug resistance of t cell lymphoma cell line.
Brief description of the drawings
Inhibiting rates of Fig. 1 .Berberine to mouse transplanting tumor.Abscissa is the time, and ordinate is gross tumor volume, single
Position mm3。
Embodiment
Embodiment provided by the invention is elaborated below in conjunction with the accompanying drawings.
1st, material and method
1.1 reagent
Berberine is purchased from Sigma-Aldrich companies.
1.2 cell culture
People's T-LBL cell line Jurkat, CTCL cell lines H9 is purchased from Unite States Standard biology product collecting center (American
Type Culture Collection), with 3 × 105/ ml density is inoculated in the RPMI1640 trainings of 10% heat fire extinguishing hyclone
Support in base, put 37 DEG C, 5%CO2, cultivate in the incubator of 95% humidity, liquid changed per 48h, experiment uses exponential phase cell.
1.3 cells breed toxicity detection
It is 3 × 10 by density5/ ml exponential phase cell suspension inoculation is in 96 orifice plates.Berberine final concentrations point
1,5,10,50,100 μM of processing cells are not arranged to, not dosing blank group is set, and each drug concentration sets three groups of multiple holes.48h
20 μ l MTT (5mg/ml) are added per hole afterwards, are continued after cultivating 4h, 2000rpm/min centrifugation 5min, abandon supernatant.Added per hole
200 μ l DMSO make crystallization fully dissolve.ELIASA measure absorption photometric value under 490nm wavelength.Calculate Berberine processing
The proliferation inhibition rate of cell：Growth inhibition ratio=(1- drug-treateds group absorbance/control group absorbance) × 100%.
The foundation of 1.4 lymphoma mouse models
4 week old female BAl BIcs/c nude mices purchase is raised in Barrier Facility animal Laminar Flow Room, raised from Shanghai Experimental Animal Center
Foster condition is：24~26 DEG C of temperature, relative humidity 40~60%.Interior uses artificial light, and free choice feeding, feed and water pass through
High-temperature disinfection treatment.The right shoulder subcutaneous vaccination 4 × 10 of every nude mice7Jurkat cell, observe within every two days after inoculating cell
Tumour growth situation, formed in injection site visual tumors within about 10 days or so.Tumor-bearing mice is carried out at random according to experimental design
Packet, it is divided into two groups i.e. control group and berberine treatment groups, wherein control group injects same amount of physiological saline,
Same amount of berberine, dosage 10mg/kg/2day is injected intraperitoneally in berberine treatment groups.All mouse observe 21
My god, the volume calculation formula of tumour is V=0.5ab2。
2nd, result
2.1Berberine significantly inhibits lymphoma cell propagation
Various concentrations berberine (1,5,10,50,100 μM) single medicine is detected respectively with mtt assay to T-LBL cell lines
Jurkat, CTCL cell line H9 inhibiting rate, are as a result prompted as drug concentration increases, and berberine is thin to above lymthoma
The inhibitory action of born of the same parents' strain propagation gradually strengthens.
Inhibiting rates of the table 1.Berberine to lymphoma cell strain
| Con | 1μM | 5μM | 10μM | 50μM | 100μM | |
| Jurkat | 0% | 0% | 35% | 40% | 50% | 64% |
| H9 | 0% | 7% | 17% | 21% | 61% | 71% |
2.2Berberine significantly inhibits the growth of mouse transplanting tumor
We further by mouse transplanting tumor model to berberine in vivo anti-lymphadenoma mechanism of action carry out
Further investigation.After being inoculated with Jurkat cell, nude inoculation position forms subcutaneous transplantation tumour.Experiment is divided into two groups, is respectively
Control group and berberine treatment groups.Measured and recorded (Fig. 1) when from diameter of tumor being about 0.5cm, find control group
Gross tumor volume increases fast compared with berberine treatment groups, big to control group at 21 days and berberine treatment group gross tumor volumes
Small compare has significant difference (P<0.05).Result above prompting berberine can significantly inhibit the life of mice-transplanted tumor
It is long.Gross tumor volume (the unit of table 2Con and Berberine group lymphoma mouse model：mm3)
| 0 | 2 | 4 | 6 | 8 | 10 | 12 | 14 | |
| Con | 78 | 85 | 115 | 199 | 428 | 539 | 594 | 735.4 |
| berberine | 74 | 88 | 95 | 97 | 98 | 111 | 124 | 153 |
Above cell experiment and zoopery show that berberine has significant suppression T lymphoma cell strains propagation and lotus
The effect of knurl mouse lymph lymphoma growth, can be as the active drug of clinical treatment t cell lymphoma.T cell lymphoma is to existing
There is a frequent resistance of chemotherapy regimen, therapeutic effect is undesirable.Find new effective medicine and method seems particularly important.
Moreover berberine is the old medicine for having listed decades, Drug safety has received long-term checking.We
Berberine application has been expanded in research, as a result prompts berberine is potential can turn into clinically effective and pacify
The medicine of complete new anti-t cell lymphoma, has great social value and economic value.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the inventive method is not departed from, can also make some improvement and supplement, and these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (4)
1. application of the berberine in the medicine for preparing treatment t cell lymphoma, described t cell lymphoma is that T lymphs are female thin
Born of the same parents' lymthoma or skin T cell lymphoma.
2. application of the berberine in medicine is prepared, it is characterised in that described medicine is used to suppress T cell lymph in animal body
The growth of knurl, described t cell lymphoma are T lymphoblastic lymphomas or skin T cell lymphoma.
3. application of the berberine in medicine is prepared, it is characterised in that described medicine is used to suppress T cell lymph in animal body
The increase of knurl volume, described t cell lymphoma are T lymphoblastic lymphomas or skin T cell lymphoma.
4. application of the berberine in medicine is prepared, it is characterised in that described medicine is used to suppress t cell lymphoma cell line
Propagation, described t cell lymphoma cell line is people's T-LBL cell line Jurkat or CTCL cell lines H9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510083058.1A CN104906088B (en) | 2015-02-16 | 2015-02-16 | Application of the berberine in the medicine for preparing treatment t cell lymphoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510083058.1A CN104906088B (en) | 2015-02-16 | 2015-02-16 | Application of the berberine in the medicine for preparing treatment t cell lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104906088A CN104906088A (en) | 2015-09-16 |
| CN104906088B true CN104906088B (en) | 2018-04-10 |
Family
ID=54075815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510083058.1A Active CN104906088B (en) | 2015-02-16 | 2015-02-16 | Application of the berberine in the medicine for preparing treatment t cell lymphoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906088B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420736A (en) * | 2016-11-14 | 2017-02-22 | 哈尔滨医科大学 | Application of berberine in preparation of drug for treating fibrinolysis system disorder related diseases |
| CN108498518B (en) * | 2017-02-24 | 2022-10-21 | 中国科学院上海药物研究所 | Application of seven-membered-ring berberine analogue and pharmaceutical composition thereof in preparation of medicines for treating multiple myeloma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421203A (en) * | 2002-09-07 | 2003-06-04 | 中山大学肿瘤防治中心 | New application of berbamine as intracorporeal antitumor drug |
-
2015
- 2015-02-16 CN CN201510083058.1A patent/CN104906088B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1421203A (en) * | 2002-09-07 | 2003-06-04 | 中山大学肿瘤防治中心 | New application of berbamine as intracorporeal antitumor drug |
Non-Patent Citations (2)
| Title |
|---|
| Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-κB pathway;Hiroki Goto等;《Cancer Science》;20120430;第103卷(第4期);第775-781页 * |
| 小檗碱对小鼠淋巴细胞体外增殖和细胞周期的影响;杜丽蕊 等;《中国免疫学杂志》;20041231;第20卷(第10期);第687-692页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104906088A (en) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104739831B (en) | Application of the berberine in the medicine for preparing treatment B cell lymphoma | |
| CN110151776A (en) | A kind of difunctional nucleosides hydrogel and its preparation method and application | |
| CN104906088B (en) | Application of the berberine in the medicine for preparing treatment t cell lymphoma | |
| CN102670578B (en) | Application of protosappanin B in preparation of bladder cancer resistant perfusion fluid | |
| CN104398526B (en) | The application of triptolide and Celastrol in antineoplastic is prepared | |
| CN103251600B (en) | Antitumor application of 2-amino-4-(3'-cyano-4'-pyrrolidyl)phenylpyrimidine compound | |
| CN101991579A (en) | Use of ursolic acid as colon tumor resistant medicament | |
| CN110123809A (en) | 5- methyl-dihydro benzofuran-application of the imidazole salt compound in pharmacy | |
| CN105219711A (en) | The culture system of a kind of CIKs cell and DC-CIKs cell | |
| CN106822904B (en) | The pharmaceutical composition and its application of inhibitor containing AKT and IRE1 inhibitor | |
| CN104940932A (en) | Application of naringenin and naringin in tumor radiotherapy | |
| CN102125698A (en) | Method for establishing mouse transplanting tumor model with normal immunologic function | |
| CN109420167B (en) | Combined medicine for treating tumor | |
| CN109793727A (en) | A kind of pharmaceutical composition and its application of effective anti-malignant tumor | |
| CN105534956A (en) | Anticancer miRNA (microRNA)-based medicinal composition for treating esophageal cancer | |
| CN101984967B (en) | Manganoporphyrin-dichloroacetic acid combined medicament for treating Lung cancer | |
| CN102232957B (en) | Use of 3-acetoxyl-8, 24-lanostadiene-21-acid in preparing medicines for preventing or treating liver cancer or breast cancer | |
| CN104306373A (en) | Application of phenyloxazole compound in preparation of medicines for treating cancers | |
| CN105055447A (en) | Applications of iron oxide nanoparticles in preparation of drug for improving erlotinib resistance | |
| CN104434948A (en) | Anti-pancreatic-cancer medicine composition and application thereof | |
| CN110496225A (en) | Stephanine and autophagy inhibitor are combined the application in preparation treatment liver-cancer medicine | |
| CN104069103B (en) | A kind of composition of medicine of Synergistic treatment cerebral glioma | |
| CN101926797A (en) | New application of tetrahydropalmatine derivatives | |
| CN102000070B (en) | Manganoporphyrin-lonidamine combined drug for treating tumor | |
| CN101601669B (en) | United medicine used for treating tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |